Natera's $349 cash price beats insurance: one test billed $4,480, insurer paid 45 cents

When Miami finance worker Mara Varona took Natera's prenatal genetic screening blood test, the company emailed and texted an offer: pay its 'prompt-pay cash price' of $349 and skip insurance entirely, saying she appeared out-of-network and insurance would likely cost her deductible balance plus $100–200. She didn't see the offers in time, let the bill route through insurance — and months later received a $750 bill, her unmet deductible, after Natera charged her insurer $4,480. The insurer paid 45 cents.

Her escape came from a Reddit thread where other women shared the tip: call Natera and ask to pay the cash rate instead of using insurance. Natera says it 'was one of the first in the industry to adopt this proactive approach,' estimating costs before billing insurance and offering the lower rate whenever a patient is out-of-network or the estimate exceeds the cash price.

The dynamics are systemic, not a Natera quirk. A 2021 JAMA Network Open study found that for half of surveyed hospitals, cash prices were lower than the median insurer-negotiated price; co-author Ge Bai, of Johns Hopkins, found insurance would have tripled the cost of her son's blood test — 'this ruined my faith' in insurers bargaining for better prices. After a 2021 federal rule forced hospitals to publish prices, researchers found cash-paying patients often pay less than insured ones for lab tests, X-rays, even joint replacements.

Bai's explanation has three parts: providers discount for cash because they skip insurance paperwork and delayed payment; cash customers shop around; and insurers can keep up to 20% of premiums for administration and profit — so lower medical spending can actually reduce an insurer's revenue, which is why 'insurance companies cannot be relied upon to get us the lowest prices.'

The counterintuitive core — paying cash beats insurance for the same test — is quantified on one invoice: $4,480 billed, 45 cents paid, $750 owed by the patient versus a $349 cash offer.

Natera operationalized the insight rather than just suffering it: proactive estimates and a cash offer turn a billing trap into a disclosed choice.

The 20% medical-loss-ratio loophole is the non-obvious engine: insurers can lose revenue when care costs less, weakening their incentive to negotiate hard.

The pattern generalizes beyond one company — post-transparency-rule research finds cash cheaper than negotiated rates at half of hospitals.

In a negotiated-price market, the list price and the insured price are both negotiable fictions; the honest number is the one a patient pays directly, same day.

Varona found the cash-rate workaround via Reddit; NPR reported the story in August 2025. Her insurers declined to explain the 45-cent payment. Natera did not answer questions about how often it provides estimates, and the source notes the practice is spreading across hospitals publishing cash prices.